PMID: 15244249Jul 13, 2004Paper

Biopolymer-mediated suramin chemotherapy in the treatment of experimental brain tumours

Acta Oncologica
Mattia BellinzonaMarco Saini

Abstract

Suramin inhibits tumour growth and neoangiogenesis by blocking several growth factor receptors. In this study the toxicity and efficacy of intralesional delivery of suramin incorporated in a controlled-release polymer were assessed in a rat 9L tumour model. Initially, the toxicity of the compound was evaluated in adult Fisher 344 rats. The animals were intracerebrally implanted with an ethylene vinyl acetate copolymer. These experiments showed early toxicity in the rats implanted with a 50% load-polymer and 100% mortality within 48 h, whereas in rats implanted with a 33% load-polymer only transient behavioural changes were observed. In a second experiment the rats were stereotactically implanted with 9L cells in the frontal region. Two days after inoculation of cells, the animals were divided into two groups: one group received a 33% suramin load-biopolymer at the tumour implantation site, while the control group received polymer implants only. The interstitial release of suramin in the brain did not produce any improvement in survival of 9L tumour-bearing rats, with a mean survival of 14.2 +/- 1 days for the suramin-treated group versus 13.8 +/- 2 for the control group (p = 0.82). We conclude that intralesional polymer-mediate...Continue Reading

References

Apr 1, 1992·Journal of the National Cancer Institute·C W TaylorS E Salmon
Jun 1, 1990·Neurology·R V La RoccaM C Dalakas
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J BittonM R Cooper
Nov 1, 1995·Glia·K H Plate, W Risau
Jan 27, 1998·Cancer Chemotherapy and Pharmacology·A R GagliardiD C Collins
May 8, 1998·Journal of Neurochemistry·W M Pardridge
Jan 29, 1999·Cancer Chemotherapy and Pharmacology·G BocciM Del Tacca
Oct 26, 1999·Journal of Neuro-oncology·M SainiM Samii
Jan 5, 2000·Journal of Neuro-oncology·H J BernsenA J van der Kogel
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J SmallNicholas J Vogelzang

❮ Previous
Next ❯

Citations

Dec 2, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Grace H HuynhFrancis C Szoka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.